Product sales — Total revenues
Gilead Sciences Product sales — Total revenues decreased by 12.1% to $6.95B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from $6.61B to $6.95B. Over 3 years (FY 2022 to FY 2025), Product sales — Total revenues shows relatively stable performance with a 2.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization, market penetration, or the launch of new therapies, while a decrease may signal patent expirations, increased competition, or declining demand for core products.
Detailed definition
This metric represents the total revenue generated from the sale of pharmaceutical products, excluding royalty, contract...
Peer comparison
This is a standard top-line revenue metric for biopharmaceutical companies, comparable to 'Net Product Sales' reported by peers like AbbVie, Amgen, or Bristol Myers Squibb.
gild_segment_product_sales_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.75B | $6.75B | $6.75B | $6.75B | $6.73B | $6.73B | $6.73B | $6.73B | $6.65B | $6.91B | $7.52B | $7.54B | $6.61B | $7.05B | $7.35B | $7.90B | $6.95B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -0.2% | +0.0% | +0.0% | +0.0% | -1.3% | +4.0% | +8.7% | +0.3% | -12.2% | +6.7% | +4.1% | +7.6% | -12.1% |
| YoY Change | — | — | — | — | -0.2% | -0.2% | -0.2% | -0.2% | -1.3% | +2.7% | +11.6% | +11.9% | -0.5% | +2.1% | -2.3% | +4.9% | +5.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's product sales — total revenues?
- Gilead Sciences (GILD) reported product sales — total revenues of $6.95B in Q1 2026.
- How has Gilead Sciences's product sales — total revenues changed year-over-year?
- Gilead Sciences's product sales — total revenues increased by 5.0% year-over-year, from $6.61B to $6.95B.
- What is the long-term trend for Gilead Sciences's product sales — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's product sales — total revenues has grown at a 2.3% compound annual growth rate (CAGR), from $26.98B to $28.92B.
- What does product sales — total revenues mean?
- The total amount of money earned from selling the company's pharmaceutical products.